JP2022507265A5 - - Google Patents

Info

Publication number
JP2022507265A5
JP2022507265A5 JP2021525753A JP2021525753A JP2022507265A5 JP 2022507265 A5 JP2022507265 A5 JP 2022507265A5 JP 2021525753 A JP2021525753 A JP 2021525753A JP 2021525753 A JP2021525753 A JP 2021525753A JP 2022507265 A5 JP2022507265 A5 JP 2022507265A5
Authority
JP
Japan
Prior art keywords
cancer
composition
compound
alkyl
electron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507265A (ja
JP7656922B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061474 external-priority patent/WO2020102529A1/en
Publication of JP2022507265A publication Critical patent/JP2022507265A/ja
Publication of JP2022507265A5 publication Critical patent/JP2022507265A5/ja
Application granted granted Critical
Publication of JP7656922B2 publication Critical patent/JP7656922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525753A 2018-11-14 2019-11-14 Rad51阻害薬としての求電子剤および求電子剤プロドラッグ Active JP7656922B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767424P 2018-11-14 2018-11-14
US62/767,424 2018-11-14
PCT/US2019/061474 WO2020102529A1 (en) 2018-11-14 2019-11-14 Electrophiles and electrophile pro-drugs as rad51 inhibitors

Publications (3)

Publication Number Publication Date
JP2022507265A JP2022507265A (ja) 2022-01-18
JP2022507265A5 true JP2022507265A5 (cg-RX-API-DMAC10.html) 2022-11-18
JP7656922B2 JP7656922B2 (ja) 2025-04-04

Family

ID=70732197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525753A Active JP7656922B2 (ja) 2018-11-14 2019-11-14 Rad51阻害薬としての求電子剤および求電子剤プロドラッグ

Country Status (6)

Country Link
US (1) US12390435B2 (cg-RX-API-DMAC10.html)
EP (1) EP3880188A4 (cg-RX-API-DMAC10.html)
JP (1) JP7656922B2 (cg-RX-API-DMAC10.html)
CN (1) CN112996493A (cg-RX-API-DMAC10.html)
CA (1) CA3114406A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020102529A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12390435B2 (en) 2018-11-14 2025-08-19 University of Pittsburgh—of the Commonwealth System of Higher Education Electrophiles and electrophile pro-drugs as RAD51 inhibitors
WO2023025263A1 (en) * 2021-08-25 2023-03-02 Ensem Therapeutics Holding (Singapore) Pte. Ltd. Systems and methods for post-translational modification-inspired drug design and screening
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110396A2 (en) 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
DK2280928T3 (en) * 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
CN102099024B (zh) * 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
CA2769624C (en) 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
WO2011041639A2 (en) * 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
WO2013116753A1 (en) 2012-02-03 2013-08-08 University Of Pittsburgh-Of The Commonwelth System Of Higher Education Fatty acids as anti-inflammatory agents
EP3283061A4 (en) 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
US10751310B2 (en) 2016-03-04 2020-08-25 University of Pittsburgh—of the Commonwealth System of Higher Education Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds
CA3039376A1 (en) 2016-10-05 2018-04-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Reversibly protected thiolated electrophilic fatty acids as prodrugs
WO2018067709A1 (en) 2016-10-05 2018-04-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Novel reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions
US12390435B2 (en) 2018-11-14 2025-08-19 University of Pittsburgh—of the Commonwealth System of Higher Education Electrophiles and electrophile pro-drugs as RAD51 inhibitors

Similar Documents

Publication Publication Date Title
Vis et al. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways
CN117919235A (zh) 一种萘酰胺化合物治疗kras突变相关疾病的用途
Mostaghel et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants
Hoy Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer
Devulapally et al. Formulation of anti-miR-21 and 4-hydroxytamoxifen co-loaded biodegradable polymer nanoparticles and their antiproliferative effect on breast cancer cells
US20220000824A1 (en) Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
Hassan et al. MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma
CN114432318A (zh) 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法
Blazek et al. Novel therapies on the horizon of hypertension management
JP2013531038A (ja) 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法
JP7197370B2 (ja) がんの予防および/または治療のための化合物、組成物および方法
JP2020516646A (ja) 前立腺癌の併用療法
JP2016515630A5 (cg-RX-API-DMAC10.html)
US20230414635A1 (en) Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors
US20200108089A1 (en) Gemcitabine Derivatives for Cancer Therapy
US20250248999A1 (en) Bavdegalutamide and combinations thereof for use in treating prostate cancer
JP6918020B2 (ja) [8−(フェニルスルホニル)−3,8−ジアザビシクロ[3.2.1]オクタ−3−イル](1h−1,2,3−トリアゾール−4−イル)メタノン
EP3861119A1 (en) Splicing-dependent transcriptional gene silencing or activation
CN109125313B (zh) 一种复合制剂及其在制备肿瘤治疗药物中的用途
Tsang et al. U1 adaptors suppress the KRAS-MYC oncogenic axis in human pancreatic cancer xenografts
WO2012109527A2 (en) Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2006003013B1 (de) NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1
Salem et al. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer
WO2014159774A1 (en) Custirsen treatment with reduced toxicity